|Day Low/High||13.60 / 13.96|
|52 Wk Low/High||6.64 / 12.83|
MORE THAN 317 MILLION COMMERCIAL LIVES AND MEDICARE/MEDICAID BENEFICIARIES NOW HAVE COVERAGE FOR MIMEDX EPIFIX
The largest member-Driven Health Care Performance Improvement Company recognizes MiMedx for its positive impact on patient care
Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.
Investors in MiMedx Group Inc saw new options become available this week, for the December 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
The Dynamic Impact of Epifix® Dehydrated Human Amnion/Chorion Membrane Allografts to be Presented at the Symposium
Q1 2017 Revenue of $72.6 Million is 36% Increase Over Q1 2016
Poster Abstracts, Booth Education and Symposia Demonstrate Clinical and Cost Effective Results of MiMedx EpiFix®, AmnioFix®, EpiCord®, AmnioCord® and AmnioFill® Allografts in Healing Chronic and Acute Wounds
NEWEST MIMEDX BOARD MEMBER IS FORMER COMMISSIONER OF THE U.S. SECURITIES & EXCHANGE COMMISSION
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACIW, ACM, BID, CAJ, CHT, GLRE, MBLY, MDXG, UEIC Downgrades: BSX, IAC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
COMPANY ALSO TO EXHIBIT AT AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS (AAOS) MEETING
AUDIT COMMITTEE FINDS NO WRONGDOING BY MIMEDX MANAGEMENT
Investors in MiMedx Group Inc saw new options begin trading this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDXG options chain for the new April 21st contracts and identified the following put contract of particular interest.
In trading on Friday, shares of MiMedx Group Inc crossed above their 200 day moving average of $8.20, changing hands as high as $8.26 per share. MiMedx Group Inc shares are currently trading up about 0.9% on the day.
ARTICLES BY RENOWNED PHYSICIANS DEMONSTRATE THE CLINICAL BENEFITS OF dHACM ALLOGRAFTS IN BURN MANAGEMENT AND THE TREATMENT OF DIFFICULT TO HEAL WOUNDS
STUDY DEMONSTRATES THAT dHACM TREATMENT EFFECTS IMPROVED CELL SURVIVAL, ENHANCED VASCULARIZATION, AND RECRUITMENT OF AUTOLOGOUS STEM CELLS WITHIN INFARCTED CARDIAC TISSUE
Investors in MiMedx Group Inc saw new options become available this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
In trading on Wednesday, shares of MiMedx Group Inc crossed below their 200 day moving average of $8.25, changing hands as low as $8.03 per share. MiMedx Group Inc shares are currently trading off about 2.5% on the day.
Former Attorney General of Louisiana, Charles C. Foti, Jr.
$246.8 Million Full Year 2016 Revenue is a 32% Increase Over 2015 and $71.6 Million Q4 2016 Revenue is a 38% Increase Over Q4 2015